Publications by authors named "Guillermo de Velasco"

Claim this Profile
R
Re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4.
Jorge Esteban-Villarrubia, Guillermo de Velasco

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study.
Álvaro Pinto-Marín, Lucía Trilla-Fuertes, Jesús Miranda Poma, Naveen S Vasudev, Eugenia García-Fernández, Guillermo de Velasco

Br J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors.
Guillermo de Velasco

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.
Ray Manneh, Javier Molina-Cerrillo, Guillermo de Velasco, Linda Ibatá, Susan Martínez

Pharmaceuticals (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.
Lucia Osorio, Tatiana P Grazioso, Guillermo de Velasco, Olatz Etxaniz, Jose Luis Pérez-Gracia

Clin Transl Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).
Javier Gavira, Edouard Auclin, Macarena Rey-Cardenas, Pritha Roy, Jose C Tapia, Guillermo de Velasco

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández, Ricardo Collado, Ricardo Fernández

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.
Lillian L Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez, Guillermo de Velasco, Eduardo Castanon Alvarez

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
Thomas Powles, Toni K Choueiri, Laurence Albiges, Katriina Peltola, Guillermo de Velasco

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.
Justine Panian, Caiwei Zhong, Sharon H Choi, Kristine Ly, Roxanne Quinn, Guillermo De Velasco

Eur Urol Focus· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, Elena Garralda, Juan Martín-Liberal

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, Elena Garralda, Juan Martín-Liberal

Nature· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.
Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba, Guillermo de Velasco

Eur Urol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.
Patricia Rioja, M Rey-Cardenas, Guillermo De Velasco

Cancer Treat Rev· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma.
Loubna Omri, Marie Naigeon, Ronan Flippot, Javier Gavira-Díaz, Jesus Poveda-Ferriols, Guillermo de Velasco

Explor Target Antitumor Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Nuria Romero-Laorden, David Lorente, Guillermo de Velasco, Rebeca Lozano, Bernardo Herrera

Eur Urol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
Jesús García-Donas, Guillermo de Velasco, Rodrigo Madurga, Jesús Chamorro, Diana Rosero

Clin Transl Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Laurence Albiges, Bradley A McGregor, Daniel Y C Heng, Giuseppe Procopio, Guillermo de Velasco

Cancer Treat Rev· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
Talal El Zarif, Amin H Nassar, Gregory R Pond, Tony Zibo Zhuang, Viraj Master, Guillermo de Velasco

J Natl Cancer Inst· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Marc-Oliver Grimm, Emilio Esteban, Philippe Barthélémy, Manuela Schmidinger, Jonas Busch, Guillermo de Velasco

Lancet Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.
Jorge Esteban-Villarrubia, Carmen Romero Ferreiro, Lucía Carril-Ajuria, Alberto Carretero-González, Roberto Iacovelli, Guillermo de Velasco

Urol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Sumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, Cristina Suárez, Martin H Voss, Guillermo de Velasco

Lancet· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is immunotherapy safe and effective for older patients with kidney cancer?
Filipa Carneiro, Guillermo de Velasco

J Geriatr Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
María Santos, Javier Lanillos, Eduardo Caleiras, Carlos Valdivia, Juan M Roldan-Romero, Guillermo de Velasco

Am J Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis